
    
      This is a phase II open label study that is looking at the VRCD combination regimen in
      patients with previously untreated low-grade Non-Hodgkin's Lymphoma. Treatment will start by
      combining oral dexamethasone and cyclophosphamide with intravenous VELCADE, rituximab.
      Chemotherapy cycles will be given as outlined below every 35-days and will continue until two
      cycles beyond complete remission (CR), toxicity, patient's withdrawal, disease progression,
      or a maximum of 8 cycles.
    
  